BofA cuts target to USD 336.00 for Alnylam Pharmaceuticals stock

Published on 10/17/2026 at 20:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are scheduled for October 29, 2026. Alnylam Pharmaceuticals stock closed at USD 231.83 on October 16, 2026, down 0.94 percent on Nasdaq.

Analyst target and market dates

BofA lowered its Alnylam target to USD 336.00 from USD 346.00 on October 9, 2026.
Alnylam Pharmaceuticals is scheduled to report third-quarter results on October 29, 2026.
Alnylam Pharmaceuticals stock closed at USD 231.83 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 0.94 percent versus the Nasdaq close of October 15, 2026.
The company had a USD 31.0 billion market capitalization and a P/E ratio of 39.16 on October 16, 2026.

Alnylam Pharmaceuticals, US02043Q1076, Illustration mit AI erstellt.

BofA cut its Alnylam Pharmaceuticals target from USD 346.00 to USD 336.00 on October 9, 2026, according to Markets Insider. The new target was 44.94 percent above the Nasdaq closing price of USD 231.83 on October 16, 2026. Alnylam Pharmaceuticals stock closed down 0.94 percent on Nasdaq against the October 15, 2026 close of USD 234.03.

Target distance remains material

The BofA change still leaves a wide gap between the analyst target and the latest US closing price. The firm retained a Buy rating while citing a more conservative view of long-term uptake and growth in the ATTR-CM market, according to Markets Insider.

Stock sits below its yearly high

Alnylam Pharmaceuticals traded within a USD 197.81 to USD 495.55 52-week range on the latest quoted market data. Its USD 31.0 billion market capitalization and 39.16 P/E ratio place valuation alongside a sizeable development pipeline, while the company remains focused on RNA interference medicines.

Results date sets the next marker

Alnylam Pharmaceuticals is estimated to report third-quarter 2026 results on October 29, 2026, before the market opens, with an earnings call scheduled for 8:30 a.m. ET, according to MarketBeat. The same source lists consensus expectations of USD 1.74 adjusted earnings per share and USD 1.43 billion in revenue for the quarter.

Comparison with peers

Alnylam Pharmaceuticals (Nasdaq, USD): minus 0.94 percent, P/E 39.16, market capitalization USD 31.0 billion.

Ionis Pharmaceuticals (Nasdaq, USD): minus 2.67 percent, P/E minus 12.41, market capitalization USD 7.1 billion.

Arrowhead Pharmaceuticals (Nasdaq, USD): minus 4.44 percent, P/E minus 24.96, market capitalization USD 7.9 billion.

Dated market close

At Lang & Schwarz, Alnylam Pharmaceuticals was last quoted at EUR 206.30 on October 16, 2026 at 10:59 p.m. CEST. On Nasdaq, the stock closed at USD 231.83 on October 16, 2026 at 4:00 p.m. EDT.

The further course of trading is shown by the continuously updated real-time quote of Alnylam Pharmaceuticals stock.